EP3634381A1 - Microneedle system for applying glucagon-like peptide analogues - Google Patents
Microneedle system for applying glucagon-like peptide analoguesInfo
- Publication number
- EP3634381A1 EP3634381A1 EP18734753.9A EP18734753A EP3634381A1 EP 3634381 A1 EP3634381 A1 EP 3634381A1 EP 18734753 A EP18734753 A EP 18734753A EP 3634381 A1 EP3634381 A1 EP 3634381A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- controlled release
- glucagon
- microneedle array
- intradermal
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Definitions
- the present invention relates to a micro needle system (MNS for short) for intradermal administration in a controlled release of glucagon-like peptide analogues.
- MNS micro needle system
- the glucagon-like peptide GLP-1 (glucagon like peptide-1) belongs to the intestinal hormones and is formed with GLP-2 in intestinal cells. GLP-1 is an insulinotropic peptide and regulates blood sugar levels. Its physiological task is to maintain a normal glucose homeostasis and a balanced energy balance. GLP-1 inhibits glucagon secretion and delays gastric emptying. GLP-1 is not suitable as a therapeutic because it has an extremely short half-life of about one minute.
- GLP-1 glycine-1
- DPP IV degradative peptidase DPP IV
- marginal molecular changes such as the replacement of an amino acid make the molecule resistant to peptidase.
- Some of the previously developed GLP-1 analogs are more potent than the body's own GLP-1 and are used as antidiabetics, but must be administered subcutaneously.
- Such antidiabetics based on glucagon-like peptide analogs or antagonists - also called incretin mimetics - are in particular exenatide, liraglutide and lixisenatide (hereafter: glucagon-like-peptide analogues) and bind to the GLP-1 receptor.
- glucagon-like peptide analogs have up to 50 amino acids and a molecular weight of up to 5 kDa. The half-life is usually more than 12 hours.
- Exanetide is preferred according to the invention.
- the skin consists of several layers. The utmost
- the stratum corneum which is a complex structure of compacted keratotic cell debris approximately 10-30 microns thick, forms a watertight membrane to protect the body.
- Microneedle systems which consist of a microneedle array (MNA) and possibly other components, can by means of a pressure force the microneedles (also:
- MNA microneedle arrays
- MNS Microneedle systems
- MNS can be used for controlled release. Especially for glucagon-like Peptide analogs have a high need for controlled release, especially for more than 12 hours (short: h) or even 24 hours, so that an antidiabetic effect for one day can be achieved or supported.
- Polyvinylpyrrolidone (short: PVP) is not possible.
- PVP is preferable for influencing the release of active ingredients compared to PVA and has a higher suitability for this purpose.
- MNS microneedle system
- glucagon-like peptide analogues together with the PVP is the subject of the formulation of the MNA and consequently is inherent to the MNA or forms a unit with the MNA.
- the MNA can be designed to be monotonous or one-piece.
- the invention therefore relates to a microneedle system containing an MNA for use in the intradermal
- a controlled release application comprising or consisting of a formulation of PVP and at least one glucagon-like peptide analog.
- the invention comprises a means comprising
- Microneedle array comprising or consisting of a
- Formulation of PVP and at least one glucagon-like Peptide analogs for use in controlled release intradermal administration are provided.
- Such an agent is, for example, a drug or antidiabetic comprising a protruding microneedle array for the controlled release of at least one glucagon-like peptide analog in an intradermal application.
- the said medicament is used for the prophylaxis and treatment of diabetes, type II diabetes, insulin resistance,
- intracutaneous administration describes according to the invention the administration of substances, here: glucagon-like peptide analogues from the MNA into the skin and requires puncturing of the microneedles into the skin.
- Invention means that the active ingredient, here: glucagon-like peptide analogues, over a period of more than 2 h, preferably more than 12 h, in particular 24 h
- the invention relates to an agent for use in the controlled release intradermal administration, wherein the controlled release period is more than 2 hours, preferably more than 12 hours, in particular 24 hours.
- a dose of up to 50 pg / MNA can be administered to glucagon-like peptide analogs in humans.
- the invention also provides a method for the controlled release of at least one glucagon-like peptide analogs in an intradermal application comprising a microneedle array comprising or consisting of a formulation of PVP and at least one glucagon-like peptide analogues.
- the invention also relates to a method for
- the formulation may consist of any PVP having a molecular weight greater than 10,000 Da.
- the proportion of PVP (weight%) in the formulation may be 50-99%, in particular 70-90%, preferably 75-80%.
- the PVP content is dependent on the residual water. Typical residual water content may be 5-20%, in particular 12-18%. At a residual water content of 16%, the PVP content is about 76% or lower, if necessary.
- the formulation may contain auxiliaries and additives, such as
- Binders or emulsifiers e.g. Carboxymethylcellulose, alginates, gelatin,
- Humectants eg glycerol, urea, trehalose, c. ) Wetting agents, eg cetyl alcohol, glycerol monostearate, d. ) Antioxidants, such as ascorbic acid, vitamin E. However, preferred are poloxamers, alginates and polysorbates (Tween).
- the proportion of poloxamer in the formulation may be 2-7%.
- the proportion of alginate in the formulation may be 2-7%.
- the proportion of polysorbates in the formulation can be 0.1-1%.
- applicator systems for applying the microneedle array (MNA) according to the invention under pressure to the skin can be used and result in a sudden load on the skin.
- the microneedle system comprising a microneedle array is configured with an applicator.
- Such applicators advantageously allow activation of a pressure mechanism to penetrate the microneedle array into the skin or stratum corneum (see, for example, WO2008091602A2, WO2016162449A1).
- the applicator system comprising a microneedle array can be configured with conventional functional objects which allow fixation on the skin as well as easy handling for pressure exertion on the skin and in particular can contain at least one fixative.
- an applicator system is one such system that includes a device that causes the microneedle array to be delivered to the skin for administration of glucagon-like peptide analogs and applied intradermally.
- the applicator system may comprise a triggering device which is controlled electrically or mechanically.
- the applicator system may include a plunger which applies or applies the microneedle array to the skin so that the microneedles penetrate into the skin.
- the triggering device may comprise, for example, a pump, a syringe or a spring, so that a piston stroke can take place with sufficient energy.
- the plunger may be of any shape and nature and is primarily intended to provide the microneedle array from a first position to a second position for delivery of the active ingredients to the skin.
- the applicator system may further include a push button or thread.
- the microneedle array may contain fixing means, which are preferably fixed by means of a pressure-sensitive adhesive strip or plaster on the skin of a patient or volunteers, also called needle plasters.
- pressure-sensitive adhesives are highly viscous substances that stick to the skin after a short light pressure, so-called pressure-sensitive adhesives (PSA). They have high cohesive and adhesive forces.
- PSA pressure-sensitive adhesives based on poly (meth) acrylates based on polyisobutylenes or based on silicones can be used.
- the fixing means may consist of a band, elastic band, rubber or belt. Such fixatives can be used to secure attachment to the body.
- Such applicator systems allow the secure positioning of the MNA of the invention for controlled release of glucagon-like peptide analogs.
- the following examples and figures are intended to explain the invention in more detail, but without limiting it.
- FIG. 1 shows in-vitro results for formulation F1, F2 and F3, which demonstrate a slower, timed release of the active substance exenatide over a time interval of up to 24 hours.
- the formulations are shown in Table 1.
- 2AGT sodium alginate, glycerol, Tween (80)
- composition of the microneedles includes the following:
- Polylvinylpyrrolidone (PVP) Type 1 MW 20-60 kDa; Type 2:
- Active substance exenatide with 50 pg is as follows:
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017112573.6A DE102017112573A1 (en) | 2017-06-07 | 2017-06-07 | Microneedle system for the application of glucagon-like peptide analogues |
PCT/EP2018/064919 WO2018224559A1 (en) | 2017-06-07 | 2018-06-06 | Microneedle system for applying glucagon-like peptide analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3634381A1 true EP3634381A1 (en) | 2020-04-15 |
Family
ID=62778874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18734753.9A Pending EP3634381A1 (en) | 2017-06-07 | 2018-06-06 | Microneedle system for applying glucagon-like peptide analogues |
Country Status (8)
Country | Link |
---|---|
US (2) | US20200129424A1 (en) |
EP (1) | EP3634381A1 (en) |
JP (2) | JP2020522354A (en) |
CN (1) | CN110769812A (en) |
BR (1) | BR112019025606A2 (en) |
CA (1) | CA3066515A1 (en) |
DE (1) | DE102017112573A1 (en) |
WO (1) | WO2018224559A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111053891A (en) * | 2019-11-15 | 2020-04-24 | 浙江工业大学 | Polypeptide nanoparticles for treating diabetes, polypeptide nanoparticle microneedles and preparation methods thereof |
DE102021118997A1 (en) | 2021-07-22 | 2023-01-26 | Lts Lohmann Therapie-Systeme Ag. | Microneedle array with antiseptics |
CN114699510A (en) * | 2021-12-29 | 2022-07-05 | 浙江湃肽生物有限公司 | Simelide microneedle array and preparation method thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004000389A2 (en) | 2002-06-25 | 2003-12-31 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
US20090202497A1 (en) * | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
AU2007288442A1 (en) * | 2006-05-09 | 2008-02-28 | Apogee Technology, Inc. | Nanofiber structures on asperities for sequestering, carrying and transferring substances |
CA2676221C (en) | 2007-01-22 | 2016-12-20 | Corium International, Inc. | Applicators for microneedles |
WO2009054990A1 (en) * | 2007-10-23 | 2009-04-30 | Alza Corporation | Transdermal sustained release drug delivery |
ES2691388T3 (en) | 2008-10-07 | 2018-11-27 | Tuo Jin | Polymeric phase transition microneedles |
JP5675952B2 (en) * | 2011-02-24 | 2015-02-25 | 久光製薬株式会社 | GLP-1 analog composition for microneedle device |
JP6211169B2 (en) * | 2014-02-27 | 2017-10-11 | 久光製薬株式会社 | Micro needle |
CN104069585B (en) * | 2014-07-03 | 2017-12-12 | 台州薇凯生物科技有限公司 | Detachable microneedle device and its manufacture method |
WO2016039418A1 (en) * | 2014-09-11 | 2016-03-17 | 久光製薬株式会社 | Microneedle device |
BR112017021439B1 (en) | 2015-04-07 | 2022-08-02 | Lts Lohmann Therapie-Systeme Ag | MICRONEEDLE SYSTEM FOR INTRADERMAL APPLICATION, METHOD FOR PRODUCING THIS MICRONEEDLE SYSTEM AND METHOD FOR INTRADERMAL APPLICATION |
CN106474620A (en) * | 2016-09-22 | 2017-03-08 | 北京化工大学 | A kind of polymer micro needle of medicine controlled release, preparation method and microneedle patch |
-
2017
- 2017-06-07 DE DE102017112573.6A patent/DE102017112573A1/en active Pending
-
2018
- 2018-06-06 CN CN201880040455.2A patent/CN110769812A/en active Pending
- 2018-06-06 BR BR112019025606-7A patent/BR112019025606A2/en unknown
- 2018-06-06 US US16/619,611 patent/US20200129424A1/en not_active Abandoned
- 2018-06-06 JP JP2019567601A patent/JP2020522354A/en active Pending
- 2018-06-06 EP EP18734753.9A patent/EP3634381A1/en active Pending
- 2018-06-06 CA CA3066515A patent/CA3066515A1/en active Pending
- 2018-06-06 WO PCT/EP2018/064919 patent/WO2018224559A1/en active Search and Examination
-
2023
- 2023-07-21 JP JP2023118800A patent/JP2023134783A/en active Pending
- 2023-11-03 US US18/386,904 patent/US20240139098A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240139098A1 (en) | 2024-05-02 |
US20200129424A1 (en) | 2020-04-30 |
DE102017112573A1 (en) | 2018-12-13 |
JP2020522354A (en) | 2020-07-30 |
BR112019025606A2 (en) | 2020-06-16 |
WO2018224559A1 (en) | 2018-12-13 |
JP2023134783A (en) | 2023-09-27 |
CA3066515A1 (en) | 2018-12-13 |
CN110769812A (en) | 2020-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3228320B1 (en) | Combination of an insulin and a glp-1 agonist | |
EP1178783B1 (en) | Device and use for increasing the transdermal permeation of medicaments | |
EP3417871B1 (en) | Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine | |
US20240139098A1 (en) | Microneedle system for applying glucagon-like peptide analogues | |
DE102006026578B4 (en) | Active substance particle-containing transdermal therapeutic system with increased active ingredient flow and process for its preparation and use | |
EP0186019A2 (en) | Medicated dressing | |
WO2011003820A1 (en) | Heat- and vibration-stable insulin preparations | |
EP1971328B1 (en) | Transdermal therapeutic system for volatile and/or thermolabile substances | |
DE102017117784A1 (en) | Applicator system comprising a microneedle array having a drug for wound healing | |
EP2506839A2 (en) | Transdermal therapeutic system for the administration of peptides | |
EP3781127B1 (en) | Microneedle system for applying interferon | |
EP3713549A1 (en) | Transdermal therapeutic system on the basis of adhesive plasticizer-polymer matrices | |
EP3448358B1 (en) | Film administration form for the trans-mucosal administration of peptide anti-diabetic drugs | |
DE102009056745A1 (en) | Transdermal therapeutic system for the administration of peptides | |
DE102022100991A1 (en) | Device for the controlled administration of a blood sugar-lowering agent | |
DE102021128912A1 (en) | OCLUSIVE PLASTER WITH FLEXIBLE BACKING | |
DE102021128911A1 (en) | DICLOFENAC CONTAINING TTS WITH DIMETHYLPROPYLENE UREA | |
DE4406332C1 (en) | Use of transdermal glyceryl tri:nitrate formulations in pregnancy | |
Sauer | Applikation von Normal-und Verzögerungsinsulin per injectionem—vorwiegend unter pharmakokinetischen Aspekten | |
DE202015009065U1 (en) | Adhesive tape containing comfrey or comfrey root extract | |
DE102009038210A1 (en) | Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist | |
AT10260U1 (en) | TRANSDERMALES PLASTER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200107 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230201 |